drugset / Trial / NCT01343186
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects
RandomizedParallel-groupTriple-blind
Summary
This study is aimed to study the pharmacokinetic characteristics(e.g. AUC, Cmax, Tmax) of Ypeginterferon alfa-2a and interferon biomarkers(e.g. 2,5-OAS, neopterin) after single dose at different levels.
Timeline
- Start
- 2011-01
- Primary completion
- 2011-05
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ypeginterferon alfa-2a | Unknown | 45 ug | Subcutaneous |
| Subject | Ypeginterferon alfa-2a | Unknown | 90 ug | Subcutaneous |
| Subject | Ypeginterferon alfa-2a | Unknown | 180 ug | Subcutaneous |
| Subject | Ypeginterferon alfa-2a | Unknown | 270 ug | Subcutaneous |
Indications
No indication recorded.